| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/26/2011 | CA2781669A1 Cyclodextrin-based polymers for therapeutic delivery |
| 05/26/2011 | CA2781547A1 Materials and methods useful for affecting tumor cell growth, migration and invasion |
| 05/26/2011 | CA2781433A1 Suppression of cancer metastasis |
| 05/26/2011 | CA2781380A1 Quinazoline derivatives |
| 05/26/2011 | CA2781300A1 Methods and compositions for treating hedgehog-associated cancers |
| 05/26/2011 | CA2781210A1 Methods and compositions for treating solid tumors and other malignancies |
| 05/26/2011 | CA2781066A1 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use |
| 05/26/2011 | CA2781063A1 Combination |
| 05/26/2011 | CA2780977A1 Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof |
| 05/26/2011 | CA2780840A1 Iodine-labeled homoglutamic acid and glutamic acid derivatives |
| 05/26/2011 | CA2780779A1 Acid salt forms of polymer-drug conjugates and alkoxylation methods |
| 05/26/2011 | CA2780777A1 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 05/26/2011 | CA2780645A1 Salt form of a multi-arm polymer-drug conjugate |
| 05/26/2011 | CA2779490A1 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
| 05/26/2011 | CA2778867A1 Substituted pyrrolidine-2-carboxamides |
| 05/26/2011 | CA2778432A1 Parenteral formulations of gemcitabine derivatives |
| 05/25/2011 | EP2325317A1 Receptor nucleic acids and polypeptides |
| 05/25/2011 | EP2325300A1 Desaturase genes and uses thereof |
| 05/25/2011 | EP2325210A1 Monoclonal antibodies against Claudin-18 for treatment of cancer |
| 05/25/2011 | EP2325205A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 05/25/2011 | EP2325203A2 Cadherin materials and methods |
| 05/25/2011 | EP2325198A1 Compositions and methods for the therapeutic use of an atonal-associated sequence |
| 05/25/2011 | EP2325193A2 Methods and compositions for therapeutic use of RNA interference |
| 05/25/2011 | EP2325186A2 Fused Bicyclic mTor Inhibitors |
| 05/25/2011 | EP2325185A1 Plk inhibitor |
| 05/25/2011 | EP2325181A1 Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
| 05/25/2011 | EP2325180A1 Chiral CIS-imidazolines |
| 05/25/2011 | EP2325179A1 Glycosidase ihhibitors and preparation thereof |
| 05/25/2011 | EP2325174A1 Sigma receptor inhibitors |
| 05/25/2011 | EP2325163A1 Platinum complex and medical compound containing same |
| 05/25/2011 | EP2324851A1 Methods of administering anti-TNFalpha antibodies |
| 05/25/2011 | EP2324846A1 Use of urease for inhibiting cancer cell growth |
| 05/25/2011 | EP2324844A2 April receptor (BCMA) and uses thereof |
| 05/25/2011 | EP2324842A1 Immunity-inducing agent |
| 05/25/2011 | EP2324839A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/25/2011 | EP2324837A1 Synthetic lipophilic inositol glycans for treatment of glucose-metabolism disorders |
| 05/25/2011 | EP2324836A1 Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino¨benzoic acid |
| 05/25/2011 | EP2324830A1 Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage |
| 05/25/2011 | EP2324825A1 Aryl ureas with angiogenesis inhibiting activity |
| 05/25/2011 | EP2324110A2 Elimination of a contaminating non-human sialic acid by metabolic competition |
| 05/25/2011 | EP2324061A1 Multispecific antibodies |
| 05/25/2011 | EP2324059A1 Anti-pamp therapeutic antibodies |
| 05/25/2011 | EP2324058A1 Biological applications of steroid binding domains |
| 05/25/2011 | EP2324026A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 05/25/2011 | EP2324025A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 05/25/2011 | EP2324024A1 Diazacarbazoles and methods of use |
| 05/25/2011 | EP2324012A1 New compounds |
| 05/25/2011 | EP2324008A1 3,4-diarylpyrazoles as protein kinase inhibitors |
| 05/25/2011 | EP2324006A2 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
| 05/25/2011 | EP2324003A1 6-substituted isoflavonoid compounds and uses thereof |
| 05/25/2011 | EP2323993A2 2,6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
| 05/25/2011 | EP2323986A2 Hetoerocyclyl carbonic acid amides as antiproliferative agents, pdkl inhibitors |
| 05/25/2011 | EP2323738A2 Use of a soluble form of hla-g in the treatment of abnormal b-lymphocyte proliferation |
| 05/25/2011 | EP2323737A2 Triazole compounds that modulate hsp90 activity |
| 05/25/2011 | EP2323690A1 Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
| 05/25/2011 | EP2323680A2 Proteins for use in diagnosing and treating infection and disease |
| 05/25/2011 | EP2323666A1 Pharmaceutical uses of lanosta-8,24-dien-3-ols |
| 05/25/2011 | EP2323664A1 Use of a cdk inhibitor for the treatment of glioma |
| 05/25/2011 | EP2323661A1 A3 adenosine receptor allosteric modulators |
| 05/25/2011 | EP2323641A2 Nyasol and analogs thereof for the treatment of estrogen receptor beta-mediated diseases |
| 05/25/2011 | EP2158207B1 Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| 05/25/2011 | EP2125748B1 Acylaminopyrazoles as fgfr inhibitors |
| 05/25/2011 | EP2021335B1 Heterocyclic compounds as inhibitors of c-fms kinase |
| 05/25/2011 | EP1868994B1 Sulfonylpyrroles as histone deacetylase inhibitors |
| 05/25/2011 | EP1515754B1 Beta-2-glycoprotein 1 is an inhibitor of angiogenesis |
| 05/25/2011 | EP1439847B1 Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| 05/25/2011 | EP1425035B1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 05/25/2011 | EP1381384B1 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
| 05/25/2011 | EP1349562B1 Inhibiting gs-fdh to modulate no bioactivity |
| 05/25/2011 | EP1335726B1 Modified prodrug forms of ap |
| 05/25/2011 | EP1317454B1 Caspase inhibitors and uses thereof |
| 05/25/2011 | EP1263463B1 Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells |
| 05/25/2011 | CN1887296B Method of inducing antitumor immunity and its application in preparing medicine |
| 05/25/2011 | CN1882698B Hypoxia-inducible protein 2 (HIG2)serving as a novel therapeutic potential target of renal cell carcinoma (RCC) |
| 05/25/2011 | CN1578663B Inhibitors of histone deacetylase |
| 05/25/2011 | CN102076853A Enhancement of drug therapy by mirna |
| 05/25/2011 | CN102076697A Substituted quinazolines and their uses for myeoloprolific and thrombotic diseases |
| 05/25/2011 | CN102076693A Substituted tricyclic derivatives against neurodegenerative diseases |
| 05/25/2011 | CN102076690A Protein kinase inhibitors |
| 05/25/2011 | CN102076689A Pyrazolo-quinazolines |
| 05/25/2011 | CN102076682A Five-membered ring compound |
| 05/25/2011 | CN102076672A Novel five-membered ring compound |
| 05/25/2011 | CN102076650A Carboxylic acid compound |
| 05/25/2011 | CN102076359A Vaccine compositions and methods |
| 05/25/2011 | CN102076354A Composition and methods for eliciting an immune response |
| 05/25/2011 | CN102076345A Liquid composition comprising cisplatin-coordinating compound |
| 05/25/2011 | CN102071239A Anti-tumor mung bean polypeptide, preparation method thereof and application thereof to tumors |
| 05/25/2011 | CN102071196A SiRNA for inhibiting canine p53 gene expression and canine cell model of p53 gene silence |
| 05/25/2011 | CN102070726A Method for safely extracting cordyceps sinensis polysaccharide |
| 05/25/2011 | CN102070725A Sulfated galactan, and preparation method and application thereof |
| 05/25/2011 | CN102070723A Agaricus bisporus polysaccharide with immunological activity as well as preparation method and application of agaricus bisporus polysaccharide |
| 05/25/2011 | CN102070715A Human antibodies that bind human TNF alpha |
| 05/25/2011 | CN102070712A VEGF-A (vascular endothelial growth factor-A) protein and use thereof |
| 05/25/2011 | CN102070700A Marsdenia tenacissima saponins H and preparation method and application thereof |
| 05/25/2011 | CN102070658A Dimer salt of steroid alkaloid and preparation and application thereof |
| 05/25/2011 | CN102070645A Deoxy-podophyllotoxin type compound and preparation and application thereof |
| 05/25/2011 | CN102070641A Monosubstituted metal phthalocyanine and synthesis and separation method and application thereof |
| 05/25/2011 | CN102070618A Compound and crystals thereof |
| 05/25/2011 | CN102070615A Nitroxyl radical anti-tumor medicaments |
| 05/25/2011 | CN102070614A Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |